Herpes Vaccine in Development Might be Effective against the Latent Virus; CBCD Reviews a Report
Rochester, NY (PRWEB) March 31, 2015 -- “Infected with the herpes simplex virus (HSV-1 or HSV-2)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement.” – Greg Bennett, CBCD
There is no herpes vaccine in the market today. However, a herpes vaccine in development has shown great promise. In tests on mice, the vaccine has proven effective against both strains of the herpes simplex virus (HSV-1 and HSV-2). However, unlike other herpes vaccine candidates, this is the first that “prevents both active and latent HSV-2 infections - the first-ever vaccine to do so.” (1) In all other HSV vaccines, scientists believed that the immune system must be exposed to the viral protein, gD-2. However, Yeshiva University team members took an opposite approach. They deleted this viral protein from the virus genome and then exposed mice to the modified virus. Surprisingly, their approach worked, though the scientists are still not sure why. (1)
Dr. William Jacobs, Jr. said that “Developing a herpes vaccine is one of the holy grails of infectious disease research. We decided to take an approach that runs counter to most of the tactics used by other scientists - and we seem to have cracked the code.” (See Einstein.yu.edu from March 10, 2015) (2) Additionally, Dr. Jacobs, Jr. said that “With herpes sores you continually get them. If our vaccine works in humans as it does in mice, administering it early in life could completely eliminate herpes latency.” (See the Howard Hughes Medical Institute, from March 7, 2015) (3) Effectively, this would also eliminate recurrent herpes outbreaks.
The Center for the Biology of Chronic Disease (CBCD) is encouraged by the success of the Yeshiva University scientists. Part of the mission of the CBCD is researching the effect of foreign DNA, such as that found in latent viruses, on human cells. Since 2003, the CBCD has warned of the dangers latent viruses pose. The Center believes removing herpes from the long list of chronic diseases will be an important step forward for medicine.
However, developing an effective, therapeutic vaccine against the genital herpes virus (HSV-2) and gaining FDA approval takes time. Until the Yeshiva University’s anti-herpes vaccine is FDA approved, the CBCD recommends that infected individuals take Novirin, a natural herpes remedy with a formula backed by clinical studies.
Click to learn more about Novirin and herpes symptoms.
The formula of Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin formula is effective against the herpes family of viruses, including HSV-1 and HSV-2. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HSV … reported a safe decrease in their symptoms following treatment with (the formula of Novirin).” (4) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (4)
Novirin can be ordered online on the product website, here: http://www.novirin.com.
Novirin is a natural antiviral dietary supplement. Its formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.
To date, Novirin is the only natural antiviral products on the market with published clinical studies that support its claims.
“Herpes simplex virus (HSV) infections impose an enormous health burden on the world’s population, making the development of an HSV vaccine a top public health priority (Shin and Iwasaki, 2013; Awasthi and Friedman, 2014). HSV-1 is the leading cause of corneal blindness worldwide and has emerged as the predominant cause of genital disease in the developed world. HSV-2 is the leading cause of genital ulcerative disease, and its high prevalence in sub-Saharan Africa contributes significantly to the spread of HIV-1 in this region. Moreover, HSV can lie dormant (or latent) in neurons for months or years before becoming active, so the health of infected individuals can be affected for life. There is, therefore, an urgent need for an effective HSV vaccine that can provide protection against infection and also prevent the virus entering a latent state.” (See Elifesciences.org, from March 10, 2015) (5)
What treatments are currently available for those infected with the herpes virus?
“Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day.” (4)
The CBCD points out that there is also the natural antiviral product, Novirin, which was designed to help the immune system target the latent HSV in those already infected. Additionally, two separate post-marketing clinical studies found that the formula of Novirin reduced the symptoms of HSV infected individuals. (4)
“We believe a vaccine that is effective against both the active and latent herpes virus will be a medical breakthrough. But, in light of the fact that there are no vaccines against the herpes virus currently on the market, the CBCD recommends that HSV infected individuals take Novirin against the latent HSV.” – Greg Bennett, CBCD
Click to learn more about Novirin and HSV.
References:
(1) Refinery29.com - Macmillen, H. "This Experimental Vaccine Could Mean The End Of Herpes." Published March 24, 2015.
http://www.refinery29.com/2015/03/84389/experimental-herpes-vaccine
(2) Albert Einstein College of Medicine - Yeshiva University - "Experimental Herpes Vaccine Upends Traditional Approach and Shows Promise." Published March 10, 2015
http://www.einstein.yu.edu/news/releases/1076/experimental-herpes-vaccine-upends-traditional-approach-and-shows-promise/
(3) Howard Hughes Medical Institute (HHMI) - Radical Vaccine Design Effective Against Herpes Viruses. Published March 7, 2015.
http://www.hhmi.org/news/radical-vaccine-design-effective-against-herpes-viruses
(4) Polansky, H., Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013. http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VH2qQNKUf90
(5) Elifesciences.org - Bolland, S., Pierce,S. "Ups and downs in the search for a Herpes simplex virus vaccine." Published March 10, 2015.
http://elifesciences.org/content/elife/4/e06883.full.pdf
Greg Bennett, CBCD, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]
Share this article